Response by Bereczki to Letter Regarding Article, “Hope Dies Last—Evidence Again Fails to Support a Neuroprotectant: Cerebrolysin for Acute Ischemic Stroke”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In clinical trials and in systematic reviews, major issues are the selection of the primary end point and the method of data analysis and interpretation. After stroke, the rate of those with independent survival is of upmost importance. I fully agree with the comment of Vester et al that case fatality is not the only important outcome measure after stroke.1
In the review of Ziganshina et al,2 none of the included trials reported on the combined outcome of death or dependence. As individual patient data meta-analysis was also not possible, the review authors chose to analyze death from any cause and did not find significant difference between the cerebrolysin-treated and …